GSC Biological and Pharmaceutical Sciences
eISSN: 2581-3250 CODEN (USA): GBPSC2
Cross Ref DOI: 10.30574/gscbps
Journal homepage: https://gsconlinepress.com/journals/gscbps/

(REVIEW ARTICLE)

Check for updates

An Overview of the Biopharmaceutics Classification System (BCS)

L. Prasanna Tarivitla * and M. Sunitha Reddy

Centre for Pharmaceutical Sciences, UCESTH, JNTUH, Hyderabad, India.

GSC Biological and Pharmaceutical Sciences, 2021, 14(02), 217–221

Publication history: Received on 11 January 2021; revised on 12 February 2021; accepted on 15 February 2021

Article DOI: https://doi.org/10.30574/gscbps.2021.14.2.0012

Abstract

The Biopharmaceutics Classification System (BCS) is an essential tool in pharmaceutical sciences, providing a scientific framework for classifying drugs based on their solubility and permeability characteristics. This system, developed in 1995, helps streamline drug development and regulatory approval processes by predicting *in vivo* drug performance from in vitro data. This paper reviews the four BCS classes, their solubility and permeability criteria, detailed procedures for determining these characteristics, and suitable formulation strategies for each class. Additionally, it explores the concept of biowaivers, which allows for the waiver of *in vivo* bioavailability and bioequivalence studies under certain conditions, primarily for BCS Class I drugs. The advantages, challenges, and limitations of biowaivers are discussed, emphasizing the need for global harmonization to fully realize the BCS's potential.

Keywords: Biopharmaceutics Classification System (BCS); Biowaivers, solubility; Permeability; Drug development; Regulatory approval; Drug classification; Oral solid dosage forms; Bioavailability; bioequivalence

1. Introduction

The Biopharmaceutics Classification System (BCS) was developed by Gordon Amidon and colleagues in 1995 to provide a scientific basis for classifying drugs based on their aqueous solubility and intestinal permeability characteristics. The primary goal of the BCS is to facilitate the drug development process, particularly for oral solid dosage forms, by predicting the *in vivo* performance of a drug product from its in vitro characteristics. This system allows for a more streamlined and cost-effective approach to drug development and regulatory approval.

The BCS divides drugs into four categories based on their solubility and permeability. Solubility is assessed by determining if the highest dose strength of a drug is soluble in 250 mL or less of aqueous media across a pH range of 1 to 7.5. Permeability is evaluated by the extent of drug absorption in humans, where a drug is considered highly permeable if more than 90% of the administered dose is absorbed. The four BCS classes are as follows:

- **Class I:** High Solubility, High Permeability
- **Class II:** Low Solubility, High Permeability
- **Class III:** High Solubility, Low Permeability
- **Class IV:** Low Solubility, Low Permeability

The application of the BCS extends to regulatory decisions, including the potential for biowaivers. A biowaiver allows for the waiver of *in vivo* bioavailability and bioequivalence studies for certain drug products, primarily those classified as BCS Class I, under specific conditions. This can significantly expedite the approval process for generic drugs, reducing both time and cost.

* Corresponding author: L. Prasanna Tarivitla

2. BCS Classification

The BCS classifies drugs into four categories:

2.1. Examples of Drugs in Each BCS Class

2.1.1. BCS Class I: High Solubility, High Permeability

Drugs that dissolve readily in aqueous media and are easily absorbed through the gastrointestinal (GI) tract.Examples of drugs in this class include Metoprolol, Propranolol, Verapamil, Acetaminophen (Paracetamol), Amoxicillin, Caffeine, Diltiazem, Lisinopril, Theophylline, Carbamazepine, Atenolol, Metformin, Hydrochlorothiazide, Warfarin, Ciprofloxacin, Levofloxacin, Omeprazole, Ketoprofen, Fluconazole, Ibuprofen .

2.1.2. BCS Class II: Low Solubility, High Permeability

Drugs that have poor solubility but are well absorbed in the GI tract. Examples of drugs in this class include Ketoconazole, Phenytoin, Danazol, Carbamazepine, Diclofenac, Glibenclamide, Itraconazole, Indomethacin, Mefenamic acid, Nifedipine, Piroxicam, Spironolactone, Sildenafil, Atorvastatin, Efavirenz, Fenofibrate, Irbesartan, Lovastatin, Telmisartan, Valsartan.

2.1.3. BCS Class III: High Solubility, Low Permeability

Drugs that dissolve easily but are not readily absorbed in the GI tract. Examples of drugs in this class include Cimetidine, Acyclovir, Atenolol, Metformin, Gabapentin, Ranitidine, Neomycin, Captopril, Enalapril, Furosemide, Riboflavin, Hydrochlorothiazide, Amlodipine, Pravastatin, Levothyroxine, Oseltamivir, Topiramate, Lamivudine, Alendronate.

2.1.4. BCS Class IV: Low Solubility, Low Permeability

Drugs that are poorly soluble and poorly absorbed in the GI tract. Examples of drugs in this class include Chlorothiazide, Furosemide, Bicalutamide, Cefuroxime axetil, Griseofulvin, Methotrexate, Rifampicin, Ritonavir, Saquinavir, Paclitaxel, Cyclosporine, Tacrolimus, Itraconazole, Amphotericin B, Capreomycin, Etoposide, Erythromycin, Loratadine, Lopinavir, Aprepitant.

2.2. Solubility and Permeability Criteria

- **Solubility:** A drug is considered highly soluble when the highest dose strength is soluble in 250 mL or less of aqueous media over a pH range of 1 to 7.5.
- **Permeability:** A drug is considered highly permeable when the extent of absorption in humans is greater than 90% of an administered dose, based on mass balance or in comparison to an intravenous reference dose.

2.3. Detailed Permeability Procedure

Permeability can be assessed through in vitro and *in vivo* studies. The Caco-2 cell model is commonly used for in vitro studies, where Caco-2 cells grown on permeable supports form a confluent monolayer . The drug solution is added to the apical side, and samples are collected from the basolateral side at various intervals, then analyzed to determine drug concentration .

For *in vivo* studies, mass balance studies involve administering the drug orally and intravenously to human subjects, collecting blood, urine, and feces samples at various time points, and analyzing these to determine the total amount of drug absorbed. The extent of absorption is calculated by comparing the fraction of the orally administered dose that is absorbed to the intravenous reference dose. A drug is classified as highly permeable if the extent of absorption is greater than 90% of the administered dose

2.4. Suitable Formulations for Different BCS Classes

2.4.1. BCS Class I: High Solubility, High Permeability

For drugs in this class, simple immediate-release formulations are typically sufficient due to their high solubility and permeability. These drugs are readily absorbed, and formulation efforts can focus on optimizing dosage forms for patient convenience and compliance. Examples include tablets and capsules with minimal excipients.

2.4.2. BCS Class II: Low Solubility, High Permeability

Formulation strategies for Class II drugs focus on enhancing solubility. Techniques such as solid dispersions, micronization, nanosizing, and the use of solubilizing agents like cyclodextrins or surfactants are common. Lipid-based formulations, such as self-emulsifying drug delivery systems (SEDDS) or self-micro

2.5. Suitable Formulations for Different BCS Classes

2.5.1. BCS Class I: High Solubility, High Permeability

For drugs in this class, simple immediate-release formulations are typically sufficient due to their high solubility and permeability. These drugs are readily absorbed, and formulation efforts can focus on optimizing dosage forms for patient convenience and compliance. Examples include tablets and capsules with minimal excipients (14).

2.5.2. BCS Class II: Low Solubility, High Permeability

Formulation strategies for Class II drugs focus on enhancing solubility. Techniques such as solid dispersions, micronization, nanosizing, and the use of solubilizing agents like cyclodextrins or surfactants are common (15). Lipid-based formulations, such as self-emulsifying drug delivery systems (SEDDS) or self-microemulsifying drug delivery systems (SMEDDS), can also improve the bioavailability of these drugs (16).

2.5.3. BCS Class III: High Solubility, Low Permeability

The primary challenge for Class III drugs is their low permeability. Formulation approaches often involve the use of permeability enhancers to facilitate drug absorption. These can include the use of surfactants, co-solvents, or the inclusion of absorption enhancers such as bile salts (17). Additionally, modifying the drug's chemical structure or using prodrugs can also be considered to improve permeability (18).

2.5.4. BCS Class IV: Low Solubility, Low Permeability

Class IV drugs present the greatest challenge in formulation due to their poor solubility and permeability. A combination of strategies used for Classes II and III may be required. This can involve solubility enhancement techniques (e.g., solid dispersions, nanosizing) alongside permeability enhancers (19). Advanced drug delivery systems, such as nanoparticles, liposomes, and targeted delivery approaches, may also be necessary to achieve adequate bioavailability (20).

3. Biowaivers

Biowaivers are regulatory provisions that allow for the waiver of *in vivo* bioavailability and bioequivalence studies, typically required for the approval of generic drug products, under certain conditions. The BCS-based biowaiver is a significant application of the BCS, aimed at reducing the need for extensive clinical testing by relying on in vitro data (21).

3.1. Criteria for BCS-Based Biowaivers

To qualify for a BCS-based biowaiver, a drug product must meet the following criteria

- **BCS Classification:** The drug must be classified as BCS Class I (high solubility and high permeability) (22).
- **Dissolution:** The drug product must exhibit rapid and similar dissolution profiles (≥85% in 30 minutes) in three different media (pH 1.2, 4.5, and 6.8) (23).
- **Excipients:** The excipients in the drug formulation must not significantly affect the drug's absorption (24).

3.2. Advantages of Biowaivers

Biowaivers offer several advantages. They can significantly shorten the drug development timeline by eliminating the need for *in vivo* bioequivalence studies (25). By relying on in vitro data, pharmaceutical companies can reduce the costs associated with clinical trials (26). Additionally, biowaivers streamline the regulatory review process, allowing for quicker approval of generic drugs (27).

3.3. Challenges and Limitations

While BCS-based biowaivers offer numerous advantages, there are also challenges and limitations. Biowaivers are primarily applicable to BCS Class I drugs. Drugs in Classes II and IV, which have solubility and permeability issues, do not qualify for biowaivers, necessitating *in vivo* studies (28). The presence of certain excipients can influence drug absorption, posing a challenge in ensuring bioequivalence (29). Moreover, different regulatory agencies may have varying criteria for biowaivers, complicating the approval process for multinational drug products (30).

4. Conclusion

The Biopharmaceutics Classification System and its application in biowaivers have revolutionized the drug development process, offering a scientific basis for predicting drug absorption and enabling more efficient regulatory decisions. By classifying drugs based on their solubility and permeability, the BCS provides a framework that can expedite the approval of safe and effective generic drug products, ultimately benefiting the pharmaceutical industry and patients alike. However, the system's limitations and the need for global regulatory harmonization must be addressed to fully realize its potential.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995). A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and *in vivo* bioavailability. *Pharmaceutical Research*, 12(3), 413-420.

[2] U.S. Food and Drug Administration (FDA). (2000). Guidance for Industry: Waiver of *In vivo* Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System.

[3] European Medicines Agency (EMA). (2010). Guideline on the Investigation of Bioequivalence.

[4] Lindenberg, M., Kopp, S., & Dressman, J. B. (2004). Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the Biopharmaceutics Classification System. *European Journal of Pharmaceutics and Biopharmaceutics*, 58(2), 265-278.

[5] Takagi, T., Ramachandran, C., Bermejo, M., Yamashita, S., Yu, L. X., & Amidon, G. L. (2006). A provisional biopharmaceutics classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. *Molecular Pharmaceutics*, 3(6), 631-643.

[6] Yu, L. X., Amidon, G. L., Polli, J. E., Zhao, H., Mehta, M. U., Conner, D. P., ... & Hussain, A. S. (2002). Biopharmaceutics classification system: the scientific basis for biowaiver extensions. *Pharmaceutical Research*, 19(7), 921-925.

[7] Benet, L. Z., Broccatelli, F., & Oprea, T. I. (2011). BDDCS applied to over 900 drugs. *The AAPS Journal*, 13(4), 519-547.

[8] Lennernäs, H., & Abrahamsson, B. (2005). The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. *Journal of Pharmacy and Pharmacology*, 57(3), 273-285.

[9] Polli, J. E., Yu, L. X., Cook, J. A., Amidon, G. L., Borchardt, R. T., Burnside, B. A., ... & Shah, V. P. (2004). Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond. *The AAPS Journal*, 6(1), 1-7.

[10] Lobenberg, R., & Amidon, G. L. (2000). Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. *European Journal of Pharmaceutics and Biopharmaceutics*, 50(1), 3-12.

[11] Dahan, A., Miller, J. M., & Amidon, G. L. (2009). Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. *The AAPS Journal*, 11(4), 740-746.

[12] Artursson, P., Palm, K., & Luthman, K. (2001). Caco-2 monolayers in experimental and theoretical predictions of drug transport. *Advanced Drug Delivery Reviews*, 46(1-3), 27-43.

[13] Balimane, P. V., & Chong, S. (2005). Cell culture-based models for intestinal permeability: a critique. *Drug Discovery Today*, 10(5), 335-343.

[14] Hubatsch, I., Ragnarsson, E. G. E., & Artursson, P. (2007). Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. *Nature Protocols*, 2(9), 2111-2119.

[15] Tiwari, G., & Tiwari, R. (2010). Bioavailability enhancement by solid dispersion method. *Journal of Pharmacy and Bioallied Sciences*, 2(2), 144-148.

[16] Hancock, B. C., & Zografi, G. (1997). Characteristics and significance of the amorphous state in pharmaceutical systems. *Journal of Pharmaceutical Sciences*, 86(1), 1-12.

[17] Leuner, C., & Dressman, J. (2000). Improving drug solubility for oral delivery using solid dispersions. *European Journal of Pharmaceutics and Biopharmaceutics*, 50(1), 47-60.

[18] Chiou, W. L., & Riegelman, S. (1971). Pharmaceutical applications of solid dispersion systems. *Journal of Pharmaceutical Sciences*, 60(9), 1281-1302.

[19] Goldberg, A. H., Gibaldi, M., & Kanig, J. L. (1965). Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures I: theoretical considerations and discussion of the literature. *Journal of Pharmaceutical Sciences*, 54(8), 1145-1148.

[20] Serajuddin, A. T. (1999). Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. *Journal of Pharmaceutical Sciences*, 88(10), 1058-1066.

[21] Sugano, K., Okazaki, A., Sugimoto, S., Tavornvipas, S., Omura, A., & Mano, T. (2007). Solubility and dissolution profile assessment in drug discovery. *Drug Metabolism and Pharmacokinetics*, 22(4), 225-254.

[22] Miller, J. M., Beig, A., Carr, R. A., Webster, G. K., & Dahan, A. (2012). The solubility–permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations. *Molecular Pharmaceutics*, 9(3), 581-590.

[23] Loftsson, T., & Brewster, M. E. (1996). Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. *Journal of Pharmaceutical Sciences*, 85(10), 1017-1025.

[24] Brewster, M. E., & Loftsson, T. (2007). Cyclodextrins as pharmaceutical solubilizers. *Advanced Drug Delivery Reviews*, 59(7), 645-666.

[25] Pouton, C. W. (2006). Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. *European Journal of Pharmaceutical Sciences*, 29(3-4), 278-287.

[26] Porter, C. J. H., & Charman, W. N. (2001). In vitro assessment of oral lipid based formulations. *Advanced Drug Delivery Reviews*, 50, S127-S147.

[27] Shah, N. H., Carvajal, M. T., Patel, C. I., Infeld, M. H., & Malick, A. W. (1994). Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. *International Journal of Pharmaceutics*, 106(1), 15-23.

[28] Sarpal, K., Pawar, Y. B., & Bansal, A. K. (2010). Self-emulsifying drug delivery systems: a strategy to improve oral bioavailability. *Current Drug Delivery*, 7(4), 398-407.

[29] Patravale, V. B., Date, A. A., & Kulkarni, R. M. (2004). Nanosuspensions: a promising drug delivery strategy. *Journal of Pharmacy and Pharmacology*, 56(7), 827-840.

[30] Mehnert, W., & Mäder, K. (2001). Solid lipid nanoparticles: production, characterization and applications. *Advanced Drug Delivery Reviews*, 47(2-3), 165-196.

[31] Gupta, A. K., Gupta, M., & Yarwood, S. J. (2007). Lipid nanoparticles: nanoarchitectures and their functional implications in drug delivery. *Chemistry & Biology*, 14(6), 638-649.

[32] Brewster, M. E., & Loftsson, T. (2007). Cyclodextrins as pharmaceutical solubilizers. *Advanced Drug Delivery Reviews*, 59(7), 645-666.